Download PDF
Pharmacopsychiatry 2007; 40(1): 1-8
DOI: 10.1055/s-2007-958520
Original Paper

© Georg Thieme Verlag KG Stuttgart · New York

Outcomes in Schizophrenia Outpatients Treated with Amisulpride or Olanzapine

A. Hofer 1 , M. A. Rettenbacher 1 , M. Edlinger 1 , R. Huber 1 , T. Bodner 1 , G. Kemmler 1 , 2 , G. Sachs 3 , W. W. Fleischhacker 1
  • 1Department of Biological Psychiatry, Innsbruck Medical University, Austria
  • 2Department of General Psychiatry, Innsbruck Medical University, Austria
  • 3Department of Psychiatry, Vienna Medical University, Austria
Further Information

Publication History

received 25. 5. 2006 revised 18. 7. 2006

accepted 25. 7. 2006

Publication Date:
27 February 2007 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction: We compared stable patients with schizophrenia who were treated with either amisulpride or olanzapine in terms of symptomatic outcome, neurocognitive functioning, functionality, and subjective outcome.

Methods: Sixty outpatients with chronic schizophrenia who had been treated with either amisulpride or olanzapine for at least six months were investigated.

Results: The scores of positive, negative, and cognitive symptoms did not differ between the two groups, but patients treated with olanzapine had significantly lower scores on the excitement and depression/anxiety components of the PANSS. With regard to cognitive variables, patients treated with amisulpride showed significantly lower values regarding verbal fluency and significantly better verbal memory than patients treated with olanzapine. Both treatment groups were comparable with respect to functional and subjective outcome variables.

Discussion: These observations add to the evidence that continuous treatment with different second-generation antipsychotics with relatively few side effects leads to comparable outcomes in patients with schizophrenia.

Key words

amisulpride - olanzapine - schizophrenia - outcome - cognition - employment - quality of life - needs

References

  • 1 Andreasen NC, Carpenter Jr WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus.  Am J Psychiatry. 2005;  162 441-449
    CrossrefPubMedGoogle Scholar
  • 2 Aschenberger S, Tucher O, Langer KW. Regensburger Wörtflüssigkeits-Test. Göttingen: Hogrefe Verlag für Psychologie 2000
  • 3 Awad AG, Voruganti LNP. Impact of atypical antipsychotics on quality of life in patients with schizophrenia.  CNS Drugs. 2004;  18 877-893
    CrossrefPubMedGoogle Scholar
  • 4 Beasley CM, Tollefson GD, Tran PV. Efficacy of olanzapine: an overview of pivotal clinical trials.  J Clin Psychiatry. 1997;  58 ((suppl 10)) 7-12
    PubMedGoogle Scholar
  • 5 Benton AS, Spreen O. Der Benton Test. Handbuch: 7. Auflage 1996
  • 6 Bymaster FP, Rasmussen K, Calligaro DO, Nelson DL, DeLapp NW, Wong DT. et al . In vitro and in vivo biochemistry of olanzapine; a novel, atypical antipsychotic drug.  J Clin Psychiatry. 1997;  58 ((suppl 10)) 28-36
    PubMedGoogle Scholar
  • 7 Corrigan PW, Reinke RR, Landsberger SA, Charate A, Toombs GA. The effects of atypical antipsychotic medications on psychosocial outcomes.  Schizophr Res. 2003;  63 97-101
    CrossrefPubMedGoogle Scholar
  • 8 Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning and Memory Test (Manual). San Antonio, TX: Psychological Corporation 1987
  • 9 Fleischhacker WW. Pharmacological treatment of schizophrenia: a review. In Maj M, Sartorius N, editors Schizophrenia. WPA Series Evidence and Experience in Psychiatry. Chichester, NY, Weinheim, Brisbane, Singapore, Toronto: John Wiley & Sons, LTD 2002 p. 75-113
    Google Scholar
  • 10 Foldemo A, Bogren L. Need assessment and quality of life in outpatients with schizophrenia: a 5-year follow-up study.  Scand J Caring Sci. 2002;  16 393-398
    CrossrefPubMedGoogle Scholar
  • 11 Harvey PD, Green MF, Keefe RSE, Velligan DI. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness.  J Clin Psychiatry. 2004;  65 361-372
    CrossrefPubMedGoogle Scholar
  • 12 Heaton RK, Chelune GJ, Taley JL, Kay GG, Curtiss G. Wisconsin Card Sorting Test Manual: Revised and Expanded. Odessa, FL: Psychological Assessment Resources 1993
  • 13 Hofer A, Baumgartner S, Edlinger M, Hummer M, Kemmler G, Rettenbacher MA. et al . Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects.  Eur Psychiatry. 2005;  20 386-394
    CrossrefPubMedGoogle Scholar
  • 14 Hofer A, Kemmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects.  J Clin Psychiatry. 2004;  65 932-939
    PubMedGoogle Scholar
  • 15 Hofer A, Rettenbacher MA, Widschwendter CG, Kemmler G, Hummer M, Fleischhacker WW. Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder.  Eur Arch Psychiatry Clin Neurosci. 2006;  256 246-255
    CrossrefPubMedGoogle Scholar
  • 16 Hummer M, Huber J. Hyperprolactinaemia and antipsychotic therapy in schizophrenia.  Curr Med Res Opin. 2004;  20 189-197
    CrossrefPubMedGoogle Scholar
  • 17 Institute of Medicine .Crossing the quality chasm: a new health system for the 21st century. Washington, DC: Institute of Medicine 2001
  • 18 Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment.  Psychopharmacology. 2002;  162 3-10
    CrossrefPubMedGoogle Scholar
  • 19 Karow A, Schnedler D, Naber D. What would the patient choose? Subjective comparison of atypical and typical neuroleptics.  Pharmacopsychiatry. 2006;  39 47-51
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.  Schizophr Bull. 1987;  13 261-276
    CrossrefPubMedGoogle Scholar
  • 21 Kemmler G, Holzner B, Neudorfer C, Meise U, Hinterhuber H. General life satisfaction and domain-specific quality of life in chronic schizophrenic patients.  Qual Life Res. 1997;  6 265-273
    PubMedGoogle Scholar
  • 22 Kluge M, Wehmeier PM, Dittmann RW, Langer F, Czekalla J, Lehmann M. et al . A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being.  Pharmacopsychiatry. 2005;  38 6-12
    PubMedGoogle Scholar
  • 23 Larsen EB, Gerlach J. Subjective experience of treatment, side effects, mental state and quality of life in schizophrenic outpatients treated with depot neuroleptics.  Acta Psychiatr Scand. 1996;  96 381-388
    PubMedGoogle Scholar
  • 24 Lehrl S. Manual zum MWT-B. Erlangen: Verlag Dr. med. D. Straube 1977
  • 25 Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual ‘atypical’ antipsychotic: a meta-analysis of randomized controlled trials.  Am J Psychiatry. 2002;  159 180-190
    CrossrefPubMedGoogle Scholar
  • 26 Lindenmayer JP, Bernstein-Hyman R, Grochowski S. Five-factor model of schizophrenia.  J Nerv Ment Dis. 1994;  182 631-638
    PubMedGoogle Scholar
  • 27 Lindenmayer JP, Grochowski S, Hyman RB. Five factor model of schizophrenia: replication across samples.  Schizophr Res. 1995;  14 229-234
    CrossrefPubMedGoogle Scholar
  • 28 Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU Side Effect Rating Scale - a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients.  Acta Psychiatr Scand. 1987;  334 ((suppl)) 1-100
    PubMedGoogle Scholar
  • 29 Marwaha S, Johnson S. Schizophrenia and employment. A review.  Soc Psychiatry Psychiatr Epidemiol. 2004;  39 337-349
    PubMedGoogle Scholar
  • 30 McGurk SR, Powchick P. The central cholinergic system and cognitive dysfunction in schizophrenia. In Sharma T, Harvey PD, editors Cognition in Schizophrenia. New York NY: Oxford University Press 2000 p. 266-285
    Google Scholar
  • 31 Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.  Schizophr Bull. 1999;  25 233-255
    CrossrefPubMedGoogle Scholar
  • 32 Mueser KT. Cognitive functioning, social adjustment, and long-term outcome in schizophrenia. In: Sharma T, Harvey PD, editors. Cognition in Schizophrenia. New York NY: Oxford University Press 2000: 15-177
    Google Scholar
  • 33 Ochoa S, Haro JM, Autonell J, Pendas A, Teba F, Marquez M. et al . Met and unmet needs of schizophrenia patients in a Spanish sample.  Schizophr Bull. 2003;  29 201-210
    CrossrefPubMedGoogle Scholar
  • 34 Olivier B. Serotonergic mechanisms in aggression.  Novartis Found Symp. 2005;  268 171-183 , discussion 183-189, 242-253
    PubMedGoogle Scholar
  • 35 Peuskens J, Möller HJ, Peuch A. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone.  Eur Neuropsychopharmacology. 2002;  12 305-310
    PubMedGoogle Scholar
  • 36 Priebe S, Heinze M, Jäckel A. Berliner Bedürfnis Inventar (BeBI). FU Berlin: Abteilung für Sozialpsychiatrie 1993
  • 37 Rettenbacher MA. Disturbances of glucose and lipid metabolism during treatment with new generation antipsychotics.  Curr Opin Psychiatry. 2005;  18 175-179
    PubMedGoogle Scholar
  • 38 Rettenbacher MA, Eder-Ischia U, Bader A, Edlinger M, Hofer A, Hummer M. et al . QTc variability in schizophrenia patients treated with antipsychotics and healthy controls.  J Clin Psychopharmacol. 2005;  25 206-210
    CrossrefPubMedGoogle Scholar
  • 39 Saleem P, Olie JP, Loo H. Social functioning and quality of life in the schizophrenic patient: advantes of amisulpride.  Int Clin Psychopharmacol. 2002;  17 1-8
    PubMedGoogle Scholar
  • 40 Sartorius N, Fleischhacker WW, Gjerris U, Kern U, Knapp M, Leonard BE. et al . The usefulness and use of second generation antipsychotic medications - an update.  Curr Opin Psychiatry. 2003;  16 ((suppl 1)) 1-44
    CrossrefPubMedGoogle Scholar
  • 41 Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O. et al . Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presenaptic and limbic selectivity.  J Pharmacol Exp Ther. 1997;  280 83-97
    PubMedGoogle Scholar
  • 42 Slade M, Loftus L, Phelan M, Thornicroft G, Wykes T. CAN: The Camberwell Assessment of Need. Gaskell, London 1999
  • 43 The WHOQOL Group . Development of the World Health Organization WHOQOL-BREF quality of life assessment.  Psychol Med. 1998;  28 551-558
    CrossrefPubMedGoogle Scholar
  • 44 Tollefson GD, Sanger TM, Lu Y, Thieme ME. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.  Arch Gen Psychiatry. 1998;  55 250-258
    CrossrefPubMedGoogle Scholar
  • 45 Van Oekelen D, Luyten WHML, Leysen JE. 5-HT2A and 5-HT2C receptors and their atypical regulation properties.  Life Sci. 2003;  72 2429-2449
    CrossrefPubMedGoogle Scholar
  • 46 Wagner M, Quednow BB, Westheide J, Schlaepfer TE, Maier W, Kühn KU. Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride.  Neuropsychopharmacology. 2005;  30 381-390
    CrossrefPubMedGoogle Scholar
  • 47 Weiden PJ, Shaw E, Mann JJ. Causes of neuroleptic noncompliance.  Psychiatr Ann. 1986;  16 571-575
    PubMedGoogle Scholar
  • 48 Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.  Int J Neuropsychopharmacol. 2005;  8 457-472
    CrossrefPubMedGoogle Scholar
  • 49 Zimmermann P, Fimm B. Testbatterie zur Aufmerksamkeitsprüfung (TAP), Version 1. Herzogenrath: Vera Fimm/Psychologische Testsysteme 2002

Correspondence

A. Hofer

Department of Biological Psychiatry·Innsbruck Medical University

Anichstrasse 35

A-6020 Innsbruck

Austria

Phone: +43/512/504 23 66 9

Fax: +43/512/504 25 26 7

Email: a.hofer@i-med.ac.at

      >